ASCO/EHA Meeting Review: Register Now for the Myeloma Crowd Round Table Interactive Webcast on June 26
ASCO/EHA Meeting Review: Register Now for the Myeloma Crowd Round Table Interactive Webcast on June 26 image
Jun 26, 2021 / 11:00AM - 02:00PM EDT
HealthTree Round Tables for Multiple Myeloma Chapter

Event Description

Six Myeloma Experts Discuss ASCO/EHA Studies

The annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) can be considered the midterms on the latest studies and findings in hematological malignancies—the American Society of Hematology (ASH) meeting in this scenario is the finals.  ASCO is held every year in late May/early June in Chicago, IL.  EHA rotates annually between major European cities.  This year both will be conducted virtually because of the pandemic.

The Myeloma Crowd Round Table Interactive Webcast on Saturday, June 26 will feature two concurrent 90 minute sessions with three myeloma experts each, one European-based, the other American.

Schedule & Agenda

person
ASCO/EHA Meetings Review: Session One
11:00AM
Jennifer Ahlstrom
Welcome and Introduction of Session One Faculty
person
ASCO/EHA Meetings Review: Session One
11:05AM
Niels van de Donk, MD
Featured studies
person
ASCO/EHA Meetings Review: Session One
11:20AM
Katja Weisel, MD
Featured studies
person
ASCO/EHA Meetings Review: Session One
11:35AM
Martin Kaiser, MD
Featured studies
person
ASCO/EHA Meetings Review: Session One
11:50AM
Full Faculty
Audience Questions & Answers
person
ASCO/EHA Meetings Review: Session Two
12:30PM
Jennifer Ahlstrom
Welcome and Introduction of Session Two Faculty
person
ASCO/EHA Meetings Review: Session Two
12:35PM
Morie Gertz, MD, MACP
Featured Studies
person
ASCO/EHA Meetings Review: Session Two
12:50PM
Faith Davies, MD, MBBCh, MRCP, FRCPath
Featured Studies
person
ASCO/EHA Meetings Review: Session Two
01:05PM
Craig Hofmeister, MD, MPH
Featured Studies
person
ASCO/EHA Meetings Review: Session Two
01:20PM
Full Faculty
Audience Questions & Answers

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Read Bio
The panelist Craig Hofmeister
Craig Hofmeister

Craig Hofmeister, MD, MPH, is Associate Professor of the Department of Hematology and Medical Oncology at Emory University School of Medicine and the Winship Cancer Institute. His practice focuses on plasma cell cancers, including plasmacytomas, multiple myeloma, AL amyloidosis, smoldering myeloma, and monoclonal gammopathies of renal significance. Dr. Hofmeister’s research interests include relapsed myeloma, improving the efficacy of stem cell transplantation, and the development of monoclonal antibodies. He has extensive experience in developing and leading clinical trials in the upfront and relapsed myeloma settings. Dr. Hofmeister was a finalist for the first Myeloma Crowd Research Initiative grants competition for his research in CAR T cell research to target the monoclonal antibody CS 1. He also serves on the steering committee of the Multiple Myeloma Research Consortium (MMRC). Dr. Hofmeister completed his residency and fellowships in hematology/oncology and transplant at the Loyola University Medical Center in Chicago, IL. He earned his medical degree at The Ohio State University College of Medicine in Columbus, OH.

Read Bio
The panelist Greg Brozeit
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Read Bio
The panelist Morie Gertz, MD, MACP
Morie Gertz, MD, MACP

Morie Gertz, MD, MACP, is the Roland Seidler, Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic in Rochester, MN. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Gertz has also served as Treasurer of the International Myeloma Society and President of Mayo Staff Officers and Councilors. He was the Chair of the Mayo Personnel Committee. Currently he serves on the American Society of Hematology Training Program Committee and the American Board of Internal Medicine Hematology Board Exam Committee. Dr. Gertz has been recognized with the 2014 Jan Waldenström Medal for Medical and Scientific Achievements in Waldenström Macroglobulinemia and is a Mayo Distinguished Clinician. He has been recognized for his contributions in amyloidosis and Waldenström macroglobulinemia, has authored more than five hundred peer-reviewed publications, and is a master of the America College of Physicians. He graduated from Northwestern University with highest distinction as a Phi Beta Kappa and received his medical degree cum laude from Loyola Medical School and was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush Presbyterian St. Luke’s Hospital in Chicago and was twice voted Resident of the Year.

Read Bio
The panelist Faith Davies, MBBCh, MRCP, MD, FRCPath
Faith Davies, MBBCh, MRCP, MD, FRCPath

Faith Davies, MBBCh, MRCP, MD, FRCPath, is a member of the faculty of the Department of Medicine at New York University Langone Health and Director of the Clinical Myeloma Program at the Perlmutter Cancer Center. She is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease. Her focus is on the biology and treatment of myeloma with an emphasis on potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into individualized treatment in the clinical setting. Prior to joining NYU Langone Health, Dr. Davies was Deputy Director of the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS). She also served as Professor of Medicine and Director of the Phase I Clinical Trials Program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute. Dr. Davies came to UAMS in 2014 from the Institute of Cancer Research and the Royal Marsden Hospital, both in London. She earned her medical degree from the College of Medicine, University of Wales. She completed her general medical training in Cardiff and Birmingham and hematology specialty training in Leeds and London.

Read Bio
The panelist Martin Kaiser, MD, RWTH
Martin Kaiser, MD, RWTH

Martin Kaiser, MD, RWTH, is a Clinician Scientist and Honorary Consultant Haematologist at The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust in London, United Kingdom. In 2018, he became Team Leader of the Myeloma Molecular Therapy Group at the ICR. Dr. Kaiser’s main research interest is the molecular characterization of multiple myeloma with the aim of designing gentler therapies tailored to patients’ needs. His team is working on state-of-the-art genetic profiling to gain insight into the evolution of myeloma and the development of treatment resistance. He is the chief investigator of the national OPTIMUM trial, which offers tailored therapy for patients with molecular high-risk disease. He is active member of the UK NCRI group, the UK Myeloma Research Alliance (UKMRA) network and the UK Myeloma Forum and serves as principal or co-investigator for several national and international myeloma trials. Prior to moving to London, Dr. Kaiser specialized in hematology-oncology at Charité University Medicine in Berlin, Germany. He earned his medical degree at the University of Aachen, Germany, where he also obtained an MD in Pathology for research on multiple myeloma microenvironment interactions.

Read Bio
The panelist Niels van de Donk, MD, PhD
Niels van de Donk, MD, PhD

Niels van de Donk, MD, PhD is a full professor of hematology at Amsterdam University Medical Center, Netherlands. His specialty is multiple myeloma and he is the principal investigator of several investigator-initiated studies. Furthermore, he is involved in translational research towards finding new targets for therapy with a focus on immune therapy. He is author or co-author of a number of books and many papers published in peer-reviewed journals. He is also secretary of the HOVON multiple myeloma working party and scientific secretary of the European Myeloma Network. He has served on the EHA Scientific Program Committee since 2018. Prior to joining the Amsterdam faculty, Dr. van de Donk completed a fellowship at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute in Boston, MA. He has also practiced hematology at University Medical Center Utrecht, Netherlands.

Read Bio
The panelist Katja Weisel, MD
Katja Weisel, MD

Katja Weisel, MD, is Professor and Deputy Director of Internal Medicine and Hematology-Oncology at the Universitätsklinikum Hamburg-Eppendorf, in Hamburg, Germany.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811